WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Tuesday, November 24, 2020 
Add Press Release News | News Feeds Feeds | Email This News Email

Non-Viral Transfection Reagents and Systems Market Analysis 2020-2030, Featuring Key Player Profiles for Altogen Biosystems, MilliporeSigma, OZ Biosciences and Thermo Fisher Scientific
Saturday, July 4, 2020

DUBLIN, June 26, 2020 /PRNewswire/ -- The "Non-Viral Transfection Reagents and Systems Market, 2020-2030" report has been added to's offering.

Over the last few years, the exponential growth in the pipeline of nucleic acid based therapies has led to the escalating interest of pharmaceutical industry in this domain. Presently, more than 2,000 trials evaluating different types of gene therapies are underway. Moreover, according to experts at the US FDA, around 40 new gene therapies are likely to be approved by 2022. In this context, it is worth highlighting that viral vectors are a crucial element in gene therapy development and manufacturing. Although, viral vectors have shown significant success in R&D, their applications are limited due to immunogenicity and toxicity related concerns, high development costs and the limitation on amount of genomic material that they can carry. Excessively high price tags associated with viral-based therapies, such as Zolgensma (USD 2.1 million) and Luxtruna (USD 850,000), have led to several reimbursement challenges, thereby decreasing patient access. Owing to the aforementioned concerns related to viral vectors, therapy developers are evaluating a variety of non-viral methods of gene delivery.

In the present scenario, non-viral transfection systems are not yet widely used in therapy development and clinical studies, primarily due to their relatively low efficiency compared to viruses. The applications of these methods are largely restricted to fundamental research, including protein and gene expression, and cell line development. However, there are a number of companies that have developed proprietary technologies and products to facilitate physical (electroporation, gene gun, microinjection and sonoporation), chemical (transfection reagents) and other non-viral methods of transfection (transposon based systems, piggyBac and magnetofection). We believe that, as the demand for advanced therapy medicinal products, which require genetic engineering, the opportunity for non-viral transfection system developers is also likely to grow.

The Non-Viral Transfection Reagents and Systems Market, 2020-2030' report features an extensive study of the various systems and technologies available for non-viral transfection, in addition to the current market landscape and future potential of product developers.

Amongst other elements, the report features:

    --  A detailed assessment of the competitive landscape of various types of
        non-viral transfection systems, including transfection reagents,
        electroporation-based transfection systems and other non-viral
        transfection systems, featuring product specific information, such as
        type of carrier used, type of molecule delivered, recommended cell type
        and price of the system. Additionally, the chapter includes information
        on non-viral transfection system developers, including information on
        year of establishment, company size and geographical location.

    --  An insightful 2X2 representation, highlighting the competitiveness
        analysis of non-viral transfection system developers captured in our
        database, taking into consideration supplier power and service strength.

    --  An analysis highlighting potential strategic partners segregated based
        on likelihood of entering into collaboration with non-viral transfection
        system developers.
    --  An analysis of the big pharma players engaged in this domain, featuring
        a heat map based on parameters, such as type of initiative, type of
        therapy and target therapeutic area.
    --  An analysis of completed, ongoing and planned clinical studies related
        to non-viral transfection systems, featuring details on registration
        year, trial phase, trial status, type of sponsor, type of therapy,
        target therapeutic area, trial design, type of patient allocation model
        used, type of trial masking adopted, type of intervention, trial
        purpose, geographical location of trial and enrolled patient population.
    --  An in-depth analysis of close to 14,000 patents related to non-viral
        transfection systems that have been filed/granted since 2017,
        highlighting key trends associated with these patents, across type of
        patents, publication year, geographical location, type of applicants,
        issuing authority/patent offices involved, CPC symbols, emerging focus
        areas, leading players, patent characteristics and geography. It also
        includes a detailed patent benchmarking and an insightful valuation

    --  A detailed publication analysis of more than 1,100 peer-reviewed,
        scientific articles that have been published since 2014, highlighting
        the key trends associated with these publications, across year of
        publication, focus area, type of molecule delivered, target therapeutic
        area, important cells and cell lines evaluated, leading players across
        different geographies and key journals within this domain.

In order to account for future uncertainties and to add robustness to the model, three forecast scenarios have been provided, portraying the conservative, base and optimistic tracks of the market's evolution. The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.

In addition, the report features detailed transcripts of interviews held with the following individuals:

    --  George Eastwood (Vice-President of Business Development, Kytopen)
    --  Claudia Andretta (Global Business Development Manager, Clinical,

A selection of companies mentioned includes:

    --  Biomaterials USA
    --  BioNTech Protein
    --  Biontex Laboratories
    --  Biopact
    --  Bio-Rad Laboratories
    --  BioWare Technologies
    --  Bristol-Myers Squibb
    --  Broad Institute
    --  BTX
    --  Canvax
    --  Caribou Biosciences
    --  Celetrix
    --  Cellectis
    --  Celsion Corporation
    --  Cosmo Bio
    --  CRISPR Therapeutics
    --  Danisco
    --  Drummond Scientific
    --  Editas Medicine
    --  Eli Lilly
    --  Emisphere Technologies
    --  enGene
    --  Enzo Life Sciences
    --  Eppendorf
    --  Exicure
    --  Exon Biosciences
    --  Eyevensys
    --  EZ Biosystems
    --  FormuMax Scientific
    --  G-Biosciences
    --  GeneCopoeia
    --  GeneDireX
    --  Genlantis
    --  Genprex
    --  GenScript
    --  Gilead Sciences
    --  GlaxoSmithKline
    --  Gradalis
    --  Helixmith
    --  Icosagen
    --  IGEA
    --  Immudicon
    --  In-Cell-Art
    --  indee labs
    --  Infinitesimal
    --  Inserm
    --  Kytopen
    --  Lemonex
    --  Locate Bio
    --  Lonza
    --  MaxCyte
    --  Merck
    --  Mirai Medical
    --  Mirus Bio
    --  Moderna
    --  Narishige
    --  NepaGene
    --  Neuromics
    --  Novartis
    --  Novo Nordisk
    --  Novozymes
    --  NTrans Technologies
    --  OpenCell Technologies
    --  OrganoLinX
    --  OZ Biosciences
    --  Pfizer
    --  pHion Therapeutics
    --  Plexxikon
    --  Polyplus-transfection
    --  Polysciences
    --  Precigen
    --  PromoCell
    --  Proteacel
    --  Qiagen
    --  Regeneron Pharmaceuticals
    --  RJH Biosciences
    --  Roche
    --  Sanofi
    --  Sino Biological
    --  SQZ Biotech
    --  Stoelting
    --  Sutter Instrument
    --  Synvolux Products
    --  Takara Bio
    --  Tecrea
    --  Thermo Fisher Scientific
    --  Touchlight Genetics
    --  T-Pro Biotechnology
    --  transOMIC technologies
    --  Tritech Research
    --  Vor Biopharma
    --  Wealtec Bioscience

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav Sage Growth Partners Rebrands New Jersey's Largest Brain and Spine Surgery Group | Nov 24, 2020
Nav GoDaddy Launches GoDaddy Corporate Domains | Nov 24, 2020
Nav Groupe Beneteau looks to IFS for its new ERP mainstay | Nov 24, 2020
Nav Donuts Inc. to Acquire Afilias, Inc. | Nov 24, 2020
Nav Turkey's Akbank Will Use FICO Optimization to Build Value in Credit Card Portfolio | Nov 24, 2020
Nav Group Ltd. to Report Third Quarter of 2020 Financial Results on December 1, 2020 U.S. Time | Nov 24, 2020
Nav Interlink Co., Ltd. Celebrates the Fifth Anniversary of the .Earth Domain Launch | Nov 24, 2020
Nav Global News App Officially Launches in Google Play and iTunes | Nov 24, 2020
Nav Unify Square Highlights Strong Customer and Partner Growth; Expands Software Services Better Enabling Remote Work | Nov 24, 2020
Nav Human Factors Engineering and Usability Testing Services Market for Medical Devices, 2020 Report - Global Forecast to 2030 | Nov 24, 2020

Submit News | View More News View More News